LucenceINSIGHT Multi-Cancer Early Detection Test: Complete Guide to Blood-Based Cancer Screening

What is LucenceINSIGHT?

LucenceINSIGHT™ is a revolutionary multi-cancer early detection (MCED) test that screens for early signals of 50+ different cancers with a simple blood draw—before symptoms appear.

Unlike traditional cancer screening that focuses on one cancer type at a time (mammogram for breast cancer, colonoscopy for colorectal cancer), LucenceINSIGHT screens for multiple cancers simultaneously, making it a powerful tool for comprehensive cancer surveillance.

Key Features

✓ Simple blood test – No invasive procedures required
✓ 50+ cancer types – Screens for cancers across multiple organ systems
✓ 99% specificity – Extremely low false-positive rate
✓ 88% accuracy – Predicts up to 2 cancer origin sites
✓ Early detection – Detects cancer signals before symptoms show
✓ Complementary screening – Use alongside routine cancer screening

How Does LucenceINSIGHT Work?

The Science: Circulating Tumor DNA (ctDNA)

Cancer cells shed fragments of DNA into the bloodstream as they grow. These fragments are called circulating tumor DNA (ctDNA), and they contain evidence of genetic alterations characteristic of cancer.

LucenceINSIGHT detects:

  • Genetic alterations in ctDNA that indicate cancer presence

  • Viral DNA from cancer-associated viruses (EBV, HPV)

  • Characteristic profiles that identify the organ of origin

The Process

Step 1: Blood CollectionA simple blood draw collects circulating DNA fragments from your bloodstream.

Step 2: DNA AnalysisAdvanced sequencing technology analyzes the DNA for cancer-associated genetic alterations.

Step 3: Signal DetectionThe test identifies whether cancer signals are present and predicts the likely origin site.

Step 4: Results & GuidanceResults are provided to you and your healthcare provider with recommendations for next steps.

What Makes LucenceINSIGHT Different?

vs. Traditional Tumor Markers (CEA, CA19-9, CA-125)

Traditional tumor markers:

  • Detect proteins made by cancer cells

  • High false-positive rates (up to 40% over 5 years)

  • Limited to specific cancer types

  • Often elevated in non-cancerous conditions

LucenceINSIGHT:

  • Detects genetic alterations in circulating DNA

  • 99% specificity (only 1% false-positive rate)

  • Screens for 50+ cancer types simultaneously

  • More specific cancer signal detection

vs. Single-Cancer Screening Tests

Traditional screening:

  • Mammogram (breast cancer only)

  • Colonoscopy (colorectal cancer only)

  • PSA test (prostate cancer only)

  • Pap smear (cervical cancer only)

LucenceINSIGHT:

  • One blood test screens for 50+ cancers

  • Non-invasive (no colonoscopy prep, no radiation)

  • Detects cancers with no standard screening (pancreatic, ovarian, liver)

  • Complements existing screening protocols

50+ Cancer Types Detected

LucenceINSIGHT screens for cancers across 10 major organ systems:

1. Breast Cancer

  • Breast cancer (all subtypes)

2. Digestive System (10 cancer types)

  • Biliary tract cancer

  • Colorectal cancer

  • Colorectal neuroendocrine tumor

  • Esophageal cancer

  • Gastrointestinal stromal tumor (GIST)

  • Liver cancer

  • Pancreatic cancer

  • Small intestine cancer

  • Stomach cancer

  • Stomach neuroendocrine tumor

3. Genitourinary System (7 cancer types)

  • Adrenal gland cancer

  • Kidney cancer (clear cell)

  • Adult Wilms tumor

  • Bladder cancer

  • Penile cancer

  • Prostate cancer

  • Testicular cancer

4. Gynecologic Cancers (5 types)

  • Cervical cancer

  • Endometrial cancer

  • Ovarian cancer

  • Ovarian germ cell and stromal tumor

  • Vulvar cancer

5. Head & Neck (4 cancer types)

  • Nasopharyngeal cancer

  • Oropharyngeal cancer

  • Salivary gland cancer

  • Laryngeal cancer

6. Lymphoid Cancers (2 types)

  • Non-Hodgkin lymphoma

  • Hairy cell leukemia

7. Musculoskeletal (2 cancer types)

  • Bone cancer

  • Soft tissue cancer

8. Myeloid Cancers (3 types)

  • Acute myeloid leukemia (AML)

  • Mast cell tumor/leukemia

  • Myeloproliferative neoplasm

9. Other Cancers

  • Myeloma

  • Eye cancer (ophthalmic)

  • Skin cancer

  • Lung cancer

  • Lung neuroendocrine tumor

Test Accuracy & Performance

99% Specificity

What this means:

  • Only 1 in 100 healthy individuals receive a false-positive result

  • Significantly reduces anxiety from false alarms

  • Minimizes unnecessary follow-up testing

Comparison:

  • Traditional tumor markers: 40% false-positive rate over 5 years

  • LucenceINSIGHT: 1% false-positive rate

88% Signal Localization Accuracy

When cancer is detected, LucenceINSIGHT predicts up to 2 possible origin sites with 88% accuracy.

20 cancer sites for signal localization:

  1. Lung

  2. Colorectum

  3. Liver

  4. Pancreas

  5. Breast

  6. Stomach

  7. Nasopharynx

  8. Gastrointestinal tract

  9. Cervix

  10. Endometrium

  11. Prostate

  12. Kidney

  13. Bladder

  14. Lymphoplasmacytic lymphoma

  15. Eye

  16. Head and neck

  17. Myeloid

  18. Non-Hodgkin lymphoma

  19. Oropharynx

  20. Skin

Why this matters:

  • Guides targeted follow-up diagnostic testing

  • Reduces time to diagnosis

  • Focuses imaging and biopsies on most likely sites

Understanding Your Results

Result 1: Cancer Signal Detected

What it means:

  • LucenceINSIGHT detected genetic alterations associated with cancer

  • Includes prediction of up to 2 possible cancer origin sites

Important notes:

  • This is NOT a cancer diagnosis

  • Some individuals may have clonal hematopoiesis (not cancer)

  • Further confirmatory diagnostic testing required

Next steps:

  • Repeat test in 6 weeks or as recommended

  • Follow healthcare provider guidance for diagnostic workup

  • Targeted imaging or biopsy based on predicted site

Result 2: Hematological Disorder Signal Detected

What it means:

  • A somatic gene mutation was detected

  • May indicate blood disorder or early blood cancer

Important notes:

  • Does not rule out other cancers

  • Not a diagnosis

Next steps:

  • Hematological evaluation recommended

  • Repeat test in 6 weeks

  • Follow-up with hematologist

Result 3: Cancer Signal Not Detected

What it means:

  • No cancer-associated alterations detected at this time

  • Negative result

Important notes:

  • Does NOT rule out cancer completely

  • False negatives can occur (low DNA shedding, small tumors)

  • Test only screens for listed cancers

Next steps:

  • Continue routine cancer screening as recommended

  • Repeat LucenceINSIGHT as advised by healthcare provider

  • Monitor for symptoms

Who Should Get Tested?

Ideal Candidates

✓ Adults age 50+Cancer risk increases significantly with age; early detection most beneficial.

✓ Individuals with elevated cancer risk:

  • Family history of cancer

  • Genetic predisposition (BRCA1/2, Lynch syndrome)

  • Previous cancer diagnosis (surveillance)

  • Exposure to carcinogens (smoking, radiation)

  • Chronic inflammatory conditions

✓ Those seeking comprehensive screening:

  • Want to screen for multiple cancers simultaneously

  • Cancers without standard screening (pancreatic, ovarian, liver)

  • Prefer non-invasive testing

✓ High-risk occupations:

  • Healthcare workers

  • Chemical/industrial workers

  • Agricultural workers (pesticide exposure)

Who Should NOT Rely Solely on LucenceINSIGHT

LucenceINSIGHT should be used IN ADDITION to routine screening, not as a replacement:

  • Continue mammograms (breast cancer)

  • Continue colonoscopy (colorectal cancer)

  • Continue Pap smears (cervical cancer)

  • Continue PSA testing (prostate cancer, if recommended)

Limitations & Important Considerations

What LucenceINSIGHT Does NOT Do

❌ Does not predict inherited cancer risk – Not a genetic risk assessment❌ Does not diagnose cancer – Positive results require confirmatory testing❌ Does not screen for every cancer type – Limited to listed cancers❌ Does not replace routine screening – Use as complementary tool

False Negatives Can Occur

Reasons for false negatives:

  • Low DNA shedding from tumor

  • Very small tumor size

  • Early-stage cancer with minimal ctDNA

  • Cancer type not included in panel

  • Technical limitations of analysis

What to do:

  • Continue routine screening

  • Monitor for symptoms

  • Repeat testing as recommended

  • Don't ignore symptoms even with negative result

Clonal Hematopoiesis

What is it?A common condition (especially in older adults) where blood cells carry certain mutations but are NOT cancer.

Key facts:

  • Not cancer

  • Linked to increased cardiovascular disease risk

  • May trigger positive signal on LucenceINSIGHT

  • Requires hematological evaluation to differentiate from cancer

Privacy & Data Security

Who Has Access to Results?

✓ You – Full access to your results✓ Your healthcare providers – With your consent

✗ Insurance companies – NOT shared without consent✗ Employers – NOT shared without consent✗ Other healthcare providers – NOT shared without consent

Cost & Accessibility

Is LucenceINSIGHT Covered by Insurance?

Coverage varies by:

  • Insurance provider

  • Policy type

  • Medical necessity determination

  • Geographic location

Recommendations:

  • Check with your insurance provider

  • Ask about pre-authorization requirements

  • Inquire about out-of-pocket costs

  • Explore payment plans if self-paying

Clinical Validation

LucenceINSIGHT is backed by peer-reviewed research published in the Journal of Clinical Oncology (2024).

Key study findings:

  • 99% specificity validated in clinical trials

  • 88% signal localization accuracy

  • Effective across multiple cancer types

  • Low false-positive rate compared to traditional markers

How to Get Tested

Step 1: Consult Your Healthcare Provider

Discuss whether LucenceINSIGHT is appropriate for your risk profile and screening needs.

Step 2: Order the Test

Your healthcare provider orders the test and provides requisition.

Step 3: Blood Draw

Visit a collection center for a simple blood draw (similar to routine blood work).

Step 4: Results

Results typically available within 2-3 weeks and shared with you and your provider.

Step 5: Follow-Up

Based on results, your provider will recommend next steps (repeat testing, diagnostic workup, or continued routine screening).

Frequently Asked Questions

Q: How often should I get tested?A: Frequency depends on your risk profile and healthcare provider recommendation. Typical intervals: annually or every 6-12 months for high-risk individuals.

Q: Can I get tested if I have a current cancer diagnosis?A: LucenceINSIGHT is designed for early detection screening, not for monitoring known cancer. Discuss with your oncologist.

Q: What if I get a positive result?A: A positive result is NOT a cancer diagnosis. Your provider will guide you through confirmatory diagnostic testing (imaging, biopsy).

Q: Is the blood draw painful?A: Similar to routine blood work—brief needle stick with minimal discomfort.

Q: How long until I get results?A: Typically 2-3 weeks from blood draw.

Q: Can I eat before the test?A: Check with your provider; typically no fasting required.

Key Takeaways

  1. LucenceINSIGHT screens for 50+ cancers with a single blood test

  2. 99% specificity means very low false-positive rate

  3. 88% accuracy in predicting cancer origin site

  4. Detects cancer signals before symptoms appear

  5. Complements routine screening—does not replace it

  6. Simple, non-invasive blood draw

  7. Results guide targeted follow-up diagnostic testing

  8. Best for adults 50+ and those with elevated cancer risk

Conclusion

LucenceINSIGHT represents a significant advancement in cancer screening, offering comprehensive multi-cancer detection with a simple blood test. Its high specificity, broad cancer coverage, and ability to detect cancer before symptoms make it a valuable tool for early detection—when treatment is most effective.

Early detection saves lives. Talk to your healthcare provider about whether LucenceINSIGHT is right for you.

References

Poh, J. et al. (2024). Journal of Clinical Oncology, 42(16): e15042.

Croswell, J. et al. (2009). Annals of Family Medicine, 7(3): 212–222.

Dorsheimer, L. et al. (2019). JAMA Cardiology, 4(1): 25-30.

Jaiswal S. et al. (2014). New England Journal of Medicine, 371(26): 2488–98.

Disclaimer: This article is for educational purposes only. LucenceINSIGHT does not diagnose cancer and should be used in addition to routine cancer screening. Always consult a qualified healthcare provider for medical advice.

กลับไปยังบล็อก